Virbac rises after H1 sales beat, confirmed outlook

Virbac SA

21/07/2026 08:42

** Virbac VIRB.PA shares rise 3.2% after the French animal health group reported H1 revenue ahead of expectations and reaffirmed its 2026 outlook at the upper end of its guidance range
** H1 revenue rose 7.4% at constant exchange rates to €768 million ($877 million), implying Q2 sales of €384 million, ahead of LSEG consensus of €381 million 
**  "Virbac's growth is increasingly driven by its product mix rather than price increases," TP ICAP Midcap analysts say, pointing to volume/mix contributing about 5.4 percentage point to revenue growth versus around 2 pp from pricing
** The company says the growth was driven by companion and farm animal businesses, supported by Supercharge platforms and the Thyronorm acquisition
** It confirms it targets for 5.5%-7.5% revenue growth and about a 17% recurring operating margin in 2026
($1 = 0.8753 euros)

(Reporting by Nathan Vifflin in Gdansk)
((nathan.vifflin@thomsonreuters.com; +48 58 769 67 13;))